Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $11.04 Analyst target: $19.83 Upside: 79.62%
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.